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Atypical antipsychotics increase dopamine (DA) release in the medial prefrontal cortex (mPFC), an effect possibly involved in the
superior effects of atypical versus classical antipsychotics on cognitive/negative symptoms.We examined the role of 5-HT1A receptors in
the mPFC on the modulation of dopaminergic activity and the mesocortical DA release in vivo. The highly selective 5-HT1A agonist BAY
x 3702 (BAY; 10–40 g/kg, i.v.) increased the firing rate and burst firing of DA neurons in the ventral tegmental area (VTA) and DA
release in theVTA andmPFC. The increase inDA release in both areaswas potentiated by nomifensine coperfusion. The selective 5-HT1A
antagonist WAY-100635 reversed the effects of BAY in both areas, and the changes in the VTA were prevented by frontocortical
transection.
The application of BAY in rat andmouse mPFC by reverse dialysis increased local extracellular DA at a low concentration (3M) and
reduced it at a higher concentration (30 M). Both effects disappeared in 5-HT1A knock-out mice. In the presence of bicuculline, BAY
reduced DA release at all concentrations. The atypical antipsychotics clozapine, olanzapine, and ziprasidone (but not haloperidol)
enhanced DA release in the mPFC of wild-type but not 5-HT1A knock-out mice after systemic and local (clozapine and olanzapine)
administration in the mPFC. Likewise, bicuculline coperfusion prevented the elevation of DA release produced by local clozapine or
olanzapine application. These results suggest that the activation ofmPFC 5-HT1A receptors enhances the activity of VTADAneurons and
mesocortical DA release. This mechanismmay be involved in the elevation of extracellular DA produced by atypical antipsychotics.
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Introduction
The ventral tegmental area (VTA) gives rise to the mesocortical
and mesolimbic dopamine (DA) systems, involved in higher
brain functions such as cognition, memory, reward, and behav-
ioral control (Glowinski et al., 1984; Williams and Goldman-
Rakic, 1995; Robbins, 2000; Tzschentke and Schmidt, 2000;
Schultz, 2004). Psychotic and cognitive/negative symptoms in
schizophrenia seem to be associated with an overactivity of the
mesolimbic pathway and a hypofunction of the mesocortical
pathway, respectively (Carlsson, 1988; Weinberger et al., 1994;
Laruelle et al., 1996; Abi-Dargham et al., 2000). Classical neuro-
leptics used to treat schizophrenia block DA D2 receptors (See-
man and Lee, 1975; Creese et al., 1976), an action that also evokes
extrapyramidal motor symptoms and hyperprolactinemia. With
few exceptions (e.g., amisulpride), second-generation (atypical)
antipsychotics display a preferential 5-HT2 versus DA D2 recep-
tor affinity and occupancy in the brain (Meltzer, 1999), although
“atypicality” may encompass more than one mechanism (Roth et
al., 2003).
Among the various aminergic receptors, there is growing in-
terest in 5-HT1A receptors as potential targets for antipsychotic
drug action (Millan, 2000). These receptors seem to contribute to
the ability of atypical (but not classical) antipsychotics to increase
cortical DA release, an effect potentially involved in the improve-
ment of negative symptoms and cognitive dysfunction in schizo-
phrenia (Rollema et al., 1997, 2000; Kuroki et al., 1999; Ichikawa
et al., 2001a).
5-HT1A receptors are located in 5-HT neurons of the raphe
nuclei, where they function as autoreceptors, and in cortical and
limbic areas (Pazos and Palacios, 1985; Pompeiano et al., 1992).
Their activation results in membrane hyperpolarization and re-
duction in neuronal activity (Sprouse and Aghajanian, 1986;
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Araneda and Andrade, 1991; Amargo´s-
Bosch et al., 2004). Likewise, 5-HT1A re-
ceptors modulate 5-HT release by presyn-
aptic and postsynaptic mechanisms
(Sharp et al., 1989; Adell et al., 1993;
Celada et al., 2001). Interestingly, DA cell
firing and DA release have been shown to
be modulated by 5-HT1A receptor ago-
nists (Arborelius et al., 1993a,b; Prisco et
al., 1994; Lejeune and Millan, 1998;
Sakaue et al., 2000). However, the mecha-
nism(s) involved and the localization of
the 5-HT1A receptors responsible for this
effect have not been fully elucidated.
The activity of VTA DA neurons is
modulated, among other areas, by the me-
dial prefrontal cortex (mPFC) (Thierry et
al., 1979, 1983; Tong et al., 1996, 1998;
Carr and Sesack, 2000a,b). This control is
exerted via direct excitatory afferents as
well as indirectly, through the laterodorsal
tegmentum (LDT)/pedunculopontine
tegmentum (PPTg) or the nucleus accum-
bens/ventral pallidum (VP) pathway
(Tzschenke and Schmidt, 2000; Adell and
Artigas, 2004; Omelchenko and Sesack,
2005) (Fig. 1). The PFC is highly enriched
in pyramidal neurons expressing 5-HT1A
receptors (also present in GABA interneu-
rons) (Santana et al., 2004), in close over-
lap with projection neurons to the VTA
(Thierry et al., 1979, 1983). Based on this
anatomical and functional evidence, we conducted the present
study under the working hypothesis that 5-HT1A receptors in the
mPFC may modulate VTA DA neuron activity and DA release in
the mesocortical pathway. Additionally, we examined whether
atypical antipsychotics increase cortical DA release through this
mechanism.
Materials andMethods
Animals and treatments.Male albino Wistar rats weighing 250 –320 g and
C57BL/6 mice 10 –12 weeks of age at the time of experiments were used
(Iffa Credo, Lyon, France). 5-HT1A receptor knock-out KO(/) mice
(referred onward as KO) had the same genetic background than their
wild-type (WT) counterparts (C57BL/6) and were engendered as gener-
ated previously at Princeton University (Princeton, NJ) (Parks et al.,
1998). From this initial source, a stable colony was grown in the animal
facility of the University of Barcelona School of Medicine (Barcelona,
Spain). Animals were kept in a controlled environment (12 h light/dark
cycle and 22 2°C room temperature) with food and water provided ad
libitum. Animal care followed the European Union regulations (Official
Journal of the European Communities L358/1, December 18, 1986) and
was approved by the Institutional Animal Care and Use Committee. For
the rat, stereotaxic coordinates (in millimeters) were taken from bregma
and duramater according to the atlas of Paxinos and Watson (1998). For
mice, coordinates were taken from bregma and top of skull according to
the atlas of Franklin and Paxinos (1997).
Bicuculline, clozapine, haloperidol, apomorphine, nomifensine, and
WAY-100635 were from Research Biochemicals (Natick, MA).R-()-2-
(4-[(chroman-2-ylmethyl)-amino]-butyl)-1,1-dioxo-benzo[d] isothia-
zolone hydrochloride (BAY) (De Vry et al., 1998) was from Bayer (Wup-
pertal, Germany), olanzapine was from Eli Lilly (Indianapolis, IN), and
ziprasidone was from Pfizer (Groton, CT). BAY was administered intra-
venously at 10 – 80g/kg (free base), and WAY-100635 was administered
intravenously at the dose of 30 –100g/kg. Except for ziprasidone, which
was used in an injectable preparation (Zeldox), drugs were dissolved in
saline at the appropriate concentrations and injected (up to 1 ml/kg)
through the femoral vein. For the assessment of local or distal effects in
microdialysis experiments, drugs were dissolved in the perfusion fluid or
water [except clozapine (dissolved in acetic acid) and olanzapine (dis-
solved in HCl)] and diluted to appropriate concentrations in artificial
CSF (aCSF). Concentrated solutions (pH adjusted to 6.5–7.4 with
NaHCO3 when necessary) were stored at80°C, and working solutions
were prepared daily by dilution in aCSF at the stated concentrations and
applied by reverse dialysis (uncorrected for drug recovery). Control rats
and mice were perfused with aCSF. The bars in the figures show the
period of drug application (corrected for the void volume of the system).
Single-unit recordings. We examined the responses of VTA DA neu-
rons to the systemic administration of drugs. Rats were anesthetized
(chloral hydrate, 400 mg/kg, i.p.) and positioned in a David Kopf stereo-
taxic frame. Thereafter, chloral hydrate was continuously administered
intraperitoneally at a dose of 50 –70 mg/kg/h using a perfusion pump (Fa
et al., 2003). Body temperature was maintained at 37°C with a heating
pad. DA neurons were recorded extracellularly with glass micropipettes
pulled from 2 mm capillary glass (World Precision Instruments, Sara-
sota, FL) on a Narishige (Tokyo, Japan) PE-2 pipette puller. Microelec-
trodes were filled with 2 M NaCl. Typically, impedance was 4 –10 M.
Single-unit extracellular recordings were amplified with a Neurodata
IR283 (Cygnus Technology, Delaware Water Gap, PA), postamplified
and filtered with a Cibertec (Madrid, Spain) amplifier and computed
on-line using a DAT 1401 plus interface system Spike2 software (Cam-
bridge Electronic Design, Cambridge, UK).
Descents in the VTA were performed at anteroposterior (AP)5.0 to
5.6, lateral (L) 0.5 to 1, and dorsoventral (DV) 7.5 to 9.0 to
record DA neurons in both the parabraquial and paranigral subdivisions.
The identification of DA neurons and burst-firing analysis was per-
formed according to the criteria of Grace and Bunney (1984), as used
previously (Celada et al., 1999). Briefly, neurons were considered dopa-
minergic if they possessed the following characteristics: 1) action poten-
Figure 1. Schematic representation of the anatomical and functional relationships between themPFC, the VTA, and the dorsal
and median raphe nuclei (DR/MnR). Pyramidal neurons of the mPFC project directly to mesocortical (but not mesoaccumbal) DA
neurons, closing amPFC–VTA circuit (Carr and Sesack, 2000b). GABAergic neurons in the VTA project to mPFC and limbic areas as
well. ThemPFCmay alsomodulate the activity of VTA neurons indirectly, including the basal ganglia circuit [e.g.,mPFC3nucleus
accumbens3VP pathway or through afferents to the LDT/PPTg, among other pathways (data not shown)] (Tzschentke and
Schmidt, 2000; Floresco et al., 2003; Sesack et al., 2003; Adell and Artigas, 2004; Omelchenko and Sesack 2005). Likewise, the
mPFC is reciprocally connected with the DR/MnR. Pyramidal neurons of the mPFC project to raphe 5-HT and GABA neurons and
modulate their activity (Aghajanian and Wang, 1977; Hajo´s et al., 1998; Peyron et al., 1998; Celada et al., 2001). In turn, 5-HT
neuronsmodulate the activity of pyramidal cells in themPFC through various receptors, in particular 5-HT1A and 5-HT2A receptors,
which are expressed by pyramidal and GABAergic neurons (Araneda and Andrade, 1991; Amargo´s-Bosch et al., 2004; Santana et
al., 2004). The pharmacological activation of these receptors in the mPFC has been shown to modulate 5-HT neuron activity and
terminal 5-HT release via descending afferents to the midbrain (Celada et al., 2001; Martı´n-Ruiz et al., 2001). In addition to the
mPFC, 5-HT1A receptors are densely expressed in the DR/MnR (autoreceptors) and in areas projecting to the mPFC, such as
the hippocampal formation (Pompeiano et al., 1992). The shaded boxes show 5-HT1A receptor-rich areas. Direct 5-HT afferents to
the VTA may also be involved in the control of DA neurons by other 5-HT receptors, notably the 5-HT2C subtype, present in
GABAergic neurons of the VTA (DiMatteo et al., 2001). Glu, Glutamate; Pyr, pyramidal neuron; ACh, acetylcholine; N. Accumbens,
nucleus accumbens; iGluR, ionotropic glutamate receptor; KA, kainic acid. Data are expressed as means SEM.
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tial duration 2.5 ms; 2) typical biphasic or triphasic waveform often
with a notch in the initial rising phase; 3) slow firing rate (recorded
neurons fired at 1–5 spikes/s in control rats); and 4) frequent presence of
bursts. The structure of bursts was defined as starting with a first inter-
spike interval of80 ms and ending with an interspike interval of160
ms (Grace and Bunney, 1984). Recorded neurons in control rats had a
14.1  2.7% of spikes fired in bursts during baseline conditions. Addi-
tional pharmacological identification was performed with intravenous
apomorphine, followed by haloperidol reversal whenever possible.
Groups of rats were subjected to transection
of the prefrontal cortex. This was performed
under chloral hydrate (400 mg/kg, i.p.) anes-
thesia using a fine metal needle (0.6 mm diam-
eter), which was positioned at AP 1.0, DV
6.8, and L0.8 and moved stereotaxically to
L 4.8. In the right hemisphere, the needle was
placed with an angle of 20° to reach AP 1.0,
DV 6.8, and L 1.2 to avoid damaging the
sinus. The transection of the cortical afferents
to the midbrain was performed by moving the
needle between1.2 and4.8 mm. The brain
areas affected by the needle descent can be seen
in plate 84 of the Paxinos and Watson (1998)
atlas for rate brain (see Results). Recordings of
VTA DA neurons were conducted 1 h after the
transection.
In vivo microdialysis. Microdialysis proce-
dures in rats and mice were conducted essen-
tially as described previously by Bortolozzi et al.
(2003) and Amargo´s-Bosch et al. (2004). Rats
were anesthetized with sodium pentobarbital
(60 mg/kg, i.p.) and implanted with 4 mm con-
centric dialysis probes (Cuprophan) in the
mPFC at AP 3.2, L 0.8, and DV 6.0.
Groups of rats were also implanted with a sec-
ond microdialysis probe (tip, 1.5 mm) in the
VTA (coordinates AP 5.3, L 2.1, and DV
8.9, with a vertical angle of 10° that placed the
probe tip at L0.6 and DV8.7). Microdialy-
sis experiments in freely moving rats were per-
formed 20 h after surgery. Probes were per-
fused with aCSF pumped at 1.5 l/min. After
an initial 100 min stabilization period, four
baseline samples were collected (20 min each)
before local (reverse dialysis) or systemic drug
administration, and successive dialysate sam-
ples were collected. In anesthetized rats, the
flow rate was set at 3l/min, and fractions were
collected every 10 min.
For mice, the manufacture of the probes was
adapted from that described previously for rats.
Surgical and microdialysis procedures were
identical to those described for rats (freely
moving), except for the dose of anesthesia (so-
dium pentobarbital, 40 mg/kg, i.p.), the length
of dialysis membrane (2 mm), and the brain
coordinates (in millimeters) of the mPFC: AP,
2.2; L,0.2; DV,3.4.
The concentration of DA in dialysate sam-
ples was determined by HPLC, using a modifi-
cation of a method described previously (Ferre´
et al., 1994). Brain dialysates were collected on
microvials containing 5 l of 10 mM perchlo-
ric acid and rapidly injected into the HPLC.
DA was amperometrically detected at 5–7.5
min with a limit of detection of 3 fmol/sam-
ple using an oxidation potential of 0.75 V.
In one experiment, we also examined the ef-
fect of BAY on dialysate 5-HT concentration,
which was determined following described
procedures (Amargo´s-Bosch et al., 2004). In this case, 5-HT was de-
tected amperometrically at 0.6 V.
Microdialysis experiments were also conducted in rats subjected to corti-
cal transection. These animals were subjected to the same procedure used in
single-unit recordings, except that the surgical procedure was done 1 d be-
fore (e.g., at the time of probe implants, under pentobarbital anesthesia).
Histology. After experimental procedures were completed, animals were
killed by an overdose of anesthetic. The brains were removed and frozen in
Figure2. A,B, Representative examples of the effect of the selective 5-HT1A agonist BAY (10–80g/kg, i.v.; injections shown
by vertical arrows) on the activity of VTA DA neurons in sham-operated (A) and cortically transected (B) rats. The integrated
firing-rate histogram (abcissa, spikes per 10 s; ordinate, time inminutes) is shown. The top traces in these panels show represen-
tative burst trains corresponding to1min recordings obtained inbaseline conditions after intravenous administrationof 80g/kg
BAY and after intravenous administration of 50g/kgWAY-100635. This representation of burst activity was generated using a
modified Spike 2 software; each vertical trace corresponds to a single bursting episode, as defined in Materials and Methods. The
percentage of spikes fired in bursts is also shown. The unit in A had firing rates of 4.2, 4.8, and 3.3 spikes/s and burst firing of 18,
42, and10%(baseline, intravenous80g/kgBAYandWAY-100635, respectively). Theunit inBhad firing rates of 1.3, 1.1, and1.6
spikes/s (baseline, intravenous 80g/kg BAY andWAY-100635, respectively) with no burst during the entire recording. Note the
dissimilar effect of BAY administration in the two units. C, D, The dose–response curves on firing rate (C) and burst firing (D) in
controls (; n 11) and in cortically transected rats (f; n 7). Dotted lines show the dose–response curves in naive and
sham-operated rats, respectively. *p 0.05 versus baseline post-ANOVA; ap 0.05 versus controls. BAY had the same effect in
naive and sham-operated rats. See Results and Table 1 for statistical analysis. Although cortical transection did not significantly
affect the baseline firing rate in the entire group of decorticated rats (see Results), this subgrouphad a significant difference versus
controls.E, The lack of effect ofWAY-100635 (30–80g/kg, i.v.) on theoverall firing rate andburst firingofVTADAneurons (n
5). F, A sagittal section of a rat brain at the approximate lateral coordinate 3.4 mm, taken from midline (Paxinos and Watson,
1998). The transection lesion is shown by arrows.WAY,WAY-100635; APO, apomorphine; HAL, haloperidol; decort, decorticated;
CPu, caudate putamen. Data are expressed as means SEM.
Dı´az-Mataix et al. • 5-HT1A Modulation of Dopamine Activity J. Neurosci., November 23, 2005 • 25(47):10831–10843 • 10833
dry ice before being sectioned (70m) with a cry-
ostat in the sagittal or coronal planes, as appropri-
ate. In some cases, recording electrodes were filled
with Pontamine sky blue to verify the recording
site. Brain sections were then stained with neutral
red, according to standard procedures, to exam-
ine the correctness of the transections. In micro-
dialysis experiments, sections were examined to
verify the correct placement of probes in the VTA
or mPFC.
Data and statistical analysis. Changes in the
firing rate or the proportion of burst firing in
DA neurons were assessed using repeated-
measures ANOVA or paired Student’s t test, as
appropriate. These values were quantified by
averaging the values during 3 min in basal con-
ditions and 1–2 min after intravenous admin-
istration (omitting the first minute).
Microdialysis results are expressed as femto-
moles per fraction (uncorrected for recovery)
and are shown in figures as percentages of basal
values (individual means of four predrug frac-
tions). Statistical analysis was performed using
ANOVA for repeated measures of the DA val-
ues during specified periods. Data are ex-
pressed as the mean SEM. Statistical signifi-
cance has been set at the 95% confidence level
(two tailed).
Results
Effects of BAY on DA cell firing: dependence on
cortical integrity
The intravenous administration of the selective 5-HT1A agonist BAY
(10–80 g/kg, i.v.; cumulative doses) slightly enhanced the firing
rate and markedly increased the burst firing of VTA DA neurons in
naive, chloral hydrate-anesthetized rats ( p 0.0005 for burst firing;
n 7; one-way, repeated-measures ANOVA). A post hoc t test re-
vealed a significant effect of all BAY doses (Fig. 2). Because 1) 5-HT1A
receptors are highly expressed in the mPFC (Amargo´s-Bosch et al.,
2004) and 2) BAY increased the firing rate of pyramidal neurons
projecting to the VTA (Dı´az-Mataix et al., 2005), we examined the
possible involvement of 5-HT1A receptors in the mPFC on the effect
of BAY on DA neuron activity.
For this purpose, a group of rats was subjected to frontocor-
tical transection (see Materials and Methods). Sham-operated
rats for these experiments (n  4) were subjected to the same
surgical procedure, with the exception that the descent of the
needle was omitted. The basal firing rate did not differ between
sham and naive rats (3.7 0.4 vs 3.5 0.5 spikes/s; n 4 and 7,
respectively). Likewise, burst firing did not differ between both
groups (14 4 vs 16 6% in sham-operated and naive rats; n
4 and 7, respectively). The effect of the administration of BAY
(10 – 80 g/kg, i.v.) on the firing rate and burst firing was com-
parable on both groups ( p 0.02, effect of the dose on firing rate,
nonsignificant effects of group, and group-by-dose interaction;
p  0.0001, effect of the dose on burst firing, nonsignificant
effects of group, and group-by-dose interaction) (Fig. 2C,D).
Therefore, the data from both groups were pooled and used to-
gether as a single control group (n 11).
When considering the effect on the entire control group, BAY
(10–80g/kg, i.v.) significantly increased the firing rate (n11;p
0.03, dose effect; one-way ANOVA; significant differences of the
intravenous doses of 40 and 80 g/kg vs baseline; post hoc t test).
Likewise, BAY markedly increased the burst firing in control rats
(n 11; p 0.0001, dose effect; one-way ANOVA; significant dif-
ferences of all doses vs baseline; post hoc t test) (Fig. 2, Table 1). The
administration of the selective 5-HT1A receptor antagonist WAY-
100635 (30–100g/kg, i.v.) significantly reduced the elevation in the
firing rate ( p0.05) and burst firing produced by BAY ( p0.0005
vs 80 g/kg BAY, i.v.; nonsignificant difference between WAY-
100635 and baseline periods; Student’s paired t test). (Fig. 2). The
administration of WAY-100635 alone did not significantly alter the
activity of VTA DA neurons (Fig. 2E).
The administration of BAY (10–80g/kg, i.v.; cumulative doses)
to cortically transected rats did not elevate the firing rate or burst
firing. Two-way ANOVA revealed a significant effect of treatment
( p0.0001) and group ( p0.02) on the firing rate compared with
control rats (n 7 and 11, respectively). The effect of BAY on DA
burst firing in cortically transected rats was not statistically signifi-
cant, whereas two-way ANOVA revealed a significant difference be-
tween controls and decorticated rats ( p 0.0001, treatment effect;
p 0.0001, treatment-by-group interaction) (Fig. 2).
In addition to the group used to assess the effect of BAY, other
groups of decorticated rats were used to examine the effect of
ziprasidone and haloperidol (see below). We assessed the effect of
cortical transection on the spontaneous activity of VTA DA neu-
rons using the data from all control and decorticated rats. When
comparing naive and sham-operated rats, we found no difference
in the overall firing rate (naive: 2.9 0.3 spikes/s, n 20; sham:
3.3 0.4 spikes/s, n 10) or in burst firing (naive: 13.0 3.7%,
n 20; sham: 16.3 3.0%, n 10), and therefore the data were
pooled and used together as a control group. Cortical transec-
tion had no significant effect on the overall firing rate (3.0 
0.2 spikes/s in controls, n  30; 2.6  0.4 spikes/s in decorti-
cated rats, n  20). However, spontaneous burst firing was
significantly reduced by cortical transection (14.1  2.7% in
controls, n 30; 3.0 1.2% in decorticated rats, n 20; p
0.002 Student’s t test).
Effect of BAY on extracellular DA concentration in the
mesocortical pathway
We used in vivo microdialysis to examine the effect of local and
systemic drug administration on the DA release in the mPFC and
Table 2. Baseline dialysate DA values
Species Condition mPFC VTA
Rat Awake, aCSF 12.4 0.9 (n 31) n.e.
Awake, aCSF BIC 60.0 10.8* (n 26) n.e.
Anesthetized, aCSF 5.4 1.1 (n 7) 6.6 1.3 (n 11)
Anesthetized, aCSF NOM 21.6 1.1* (n 11) 17.9 5.0* (n 5)
Anesthetized, aCSF NOM, sham n.e. 12.1 1.4* (n 7)
Anesthetized, aCSF NOM, lesioned n.e. 19.9 4* (n 6)
Mice Awake, aCSF, WT 8.4 0.8 (n 65) n.e.
Awake, aCSF, KO 9.0 1.0 (n 61) n.e.
Data are expressed in femtomoles per 20min fraction for awake animals and femtomoles per 10min fraction for anesthetized animals (1.5 and 3l/min flow
rates, respectively; see Materials and Methods). *p 0.05 versus a CSF alone. n.e., Not examined; BIC, bicuculline (30M); NOM, nomifensine (10M).
Table 1. Firing characteristics and effect of BAY on VTA DA neurons in control and cortically transected rats
Firing rate
(spikes/s)
% of spikes fired
in burst
Mean number of
spikes per burst
Number of
bursts in 1 min
Spikes in burst
in 1 min
Basal
Controls (n 11) 3.6 0.3 15 4 2.7 0.2 13 3 36 11
Lesioned (n 7) 1.7 0.4* 2 2* 2 (2) 1 1* 2 1*
BAY (80g/kg)
Controls (n 11) 4.6 0.5 49 6 3.4 0.3 41 6 149 28
Lesioned (n 7) 2.1 0.5* 3 3* 2 (1) 2 2* 4 4*
*p 0.05 versus the corresponding value in control rats. Numbers in parentheses are the number of neurons that showed burst.
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VTA of rats. Baseline DA values in dialysates obtained in various
experimental conditions are shown in Table 2.
We examined the effect of BAY on DA release in the mesocor-
tical pathway. In the first series of experiments, to mimic the
conditions of electrophysiological recordings, rats were anesthe-
tized with chloral hydrate, and the drug was administered intra-
venously through the femoral vein. Rats were implanted with two
dialysis probes in the mPFC and VTA. In the first experiment, the
administration of BAY (10 – 40 g/kg, i.v.) increased extracellu-
lar DA to 153 11% of baseline in the mPFC and to 118 6% in
the VTA ( p 0.001, time effect for mPFC; p 0.04, time effect
for VTA; repeated-measures ANOVA; n  7 in each area) (Fig.
3). Given that 1) BAY increased burst firing of DA neurons and 2)
changes in phasic DA release are strongly dependent on reuptake
blockade (Floresco et al., 2003), we repeated these experiments in
the presence of nomifensine (10 M) in the aCSF used to perfuse
the dialysis probes.
The addition of nomifensine to the aCSF increased the base-
line DA values 4-fold in the mPFC and 2.5-fold in the VTA (Table
2). In these conditions, the administration of BAY elevated extra-
cellular DA to 228 16% in the mPFC and to 132 6% in the
VTA ( p  0.0001 for both regions; time effect; repeated-
measures ANOVA; n 8 for mPFC; n 5 for VTA; VTA samples
from three rats were lost during HPLC analysis). When consid-
ering the absolute DA values, the maximal DA elevation pro-
duced by BAY in the mPFC was 7.9  1.4 fmol/fraction in the
standard dialysis fluid and 48.0 2.9 fmol/fraction in the dialysis
fluid containing 10 M nomifensine. Two-way ANOVA revealed
a significant effect of nomifensine on the elevation of DA release
induced by BAY ( p  0.0001; significant effect of time and of
time-by-group interaction) (Fig. 3). WAY-100635 injected intra-
venously at the dose of 50 g/kg was unable to reverse the eleva-
tion of extracellular DA induced by BAY (n  3). Therefore, a
higher dose was used in subsequent experiments. In a group of
five rats, WAY-100635 (100g/kg, i.v.) significantly reversed the
effect of BAY in the mPFC ( p  0.0001; time effect; repeated-
measures ANOVA), although it did not reach statistical signifi-
cance in the VTA, likely because of the small effect size of BAY in this
region and the limited number of rats used in the VTA (n 3).
In additional experiments, we examined the effect of the cor-
tical transection on the BAY-induced elevation of the extracellu-
lar DA concentration in the VTA of anesthetized rats. The intra-
venous administration of BAY (10, 20, and 40 g/kg, i.v.)
elevated DA concentration to a maximal value of 144  20% of
baseline in sham-operated rats ( p 0.001; time effect; repeated-
measures ANOVA). This effect was not statistically different
from that seen in naive rats (n  5; p  0.0001, time effect;
nonsignificant effect of group or time-by-group interaction)
(Fig. 3B,C). When considering all rats together, BAY elevated the
DA concentration to a maximal value of 139  12% of baseline
(n  12). This effect was totally abolished in rats subjected to
cortical transection. Two-way ANOVA revealed a significant dif-
ference between the effect of BAY on cortically transected rats
(n  6) compared with controls (sham and naive; n  12; p 
0.02, time effect; p  0.001, group effect; p  0.001, time-by-
group interaction) (Fig. 3C).
Local effect of BAY on extracellular DA concentration in rat
andmouse mPFC
Subsequent experiments in rats and mice were conducted in
freely moving animals. The local application of BAY in rat mPFC
at a low concentration (3 M; five fractions) significantly in-
creased the extracellular DA concentration to 158 12% of base-
Figure3. Effect of theadministrationofBAY (10–40g/kg, i.v.) on theDAconcentration in
dialysates from the mPFC (A) and VTA (B, C) of anesthetized rats. A, The administration of BAY
moderately elevated DA concentration in rats whose probes were perfused with normal aCSF
(n 7;F), an effect reversed byWAY-100635 (50g/kg, i.v.). The DA elevation produced by
BAY was more marked when probes were perfused with an aCSF containing 10 M nomin-
fensine (n 8). Two groups of rats of three and five animals, respectively, were injected with
BAY ( andf, respectively). BAY elevated DA similarly in both groups. The administration of
intravenous 100g/kg WAY-100635 (f; n 5) reversed the effect of BAY, whereas a lower
dose (50g/kg, i.v.;; n 3) did not. B, Similarly, BAY elevated DA concentration in dialy-
sates from the VTAwhenmicrodialysis probeswere perfusedwith 10Mnomifensine (f; n
5). BAY administration induced only a verymoderate but statistically significant elevation of DA
when probes were perfusedwith an aCSF devoid of nomifensine (F; n 7). Control rats (n
3 inmPFC; n 4 in VTA)were given injections of saline (VTA probes of controls were perfusedwith
normal aCSF). C, The intravenous administration of BAY (10, 20, and 40g/kg) elevated the extra-
cellularDAconcentration in theVTAof sham-operated rats (F;n7; aCSF containing10Mnomi-
fensine)asitdidinnaiverats(B).Thedottedlineshowstheeffect innaiveandshamrats(n12).This
effectwastotallyabolishedbycorticaltransection(Œ;n6).SeeResultsforstatisticalanalysis.WAY,
WAY-100635; NOM, nomifensine. Data are expressed asmeans SEM.
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line ( p  0.0001; time effect; repeated-measures ANOVA; n 
5). However, increasing the dose to 10 M abolished this effect
(103–114% of baseline), and the perfusion of 30 M BAY (five
fractions at each concentration) significantly reduced DA release
to 51  7% of baseline ( p  0.0001; time effect; repeated-
measures ANOVA; n 5) (Fig. 4A).
Likewise, the perfusion of 3 and 30 M in the mPFC for the
entire experimental period resulted in a sustained increase (max-
imal effect, 178 18%) and decrease (maximal effect, 39 6%),
respectively, in the DA release in the mPFC ( p 0.0005 for 3M;
p 0.0001 for 30 M; repeated-measures ANOVA; n 6 and 5,
respectively). The perfusion of aCSF for the entire experimental
period did not alter dialysate DA concentrations (n  5) (Fig.
4B). In contrast to DA, the local perfusion of 3 M BAY induced
a sustained reduction in 5-HT release in the mPFC (maximal
reduction to 57 4% of baseline; p 0.001; repeated-measures
ANOVA; n  5; data not shown) as reported previously in the
range 1–100 M (Casanovas et al., 1999).
The biphasic concentration–response curve suggested the in-
volvement of different populations of 5-HT1A receptors at lower
and higher concentrations of BAY that would control the meso-
cortical DA release in an opposite condition. Because 5-HT1A
receptors have been reported to be expressed by GABAergic in-
terneurons in the mPFC (Santana et al., 2004), we examined the
effect of BAY in rat mPFC during the coperfusion of bicuculline
(30 M) to block local GABAA-mediated inputs onto pyramidal
neurons. The perfusion of 30 M bicuculline resulted in a stable
increase in DA release during the entire experimental period (Ta-
ble 2). In rats whose probes were perfused with aCSF containing
bicuculline, BAY significantly reduced DA release at all concen-
Figure 5. A, The perfusion of aCSF in the mPFC did not alter the extracellular DA concentra-
tion in the mPFC of WT (E; n 6) and 5-HT1A KO mice (F; n 6). B, Effect of the local
application of BAY at 3, 10, and 30M in themPFC on the local DA release inWT (E;n 4) and
5-HT1A KO mice (F; n 4). As observed in rat mPFC, BAY exerted a biphasic effect on DA
release, with an increase at 3M and a reduction at 30M. In mice, the 10M concentration
appeared to also reduce extracellular DA. Both effects were absent in 5-HT1A KO mice. See
Results for statistical details. Data are expressed as means SEM.
Figure 4. A, Effect of the local application of BAY by reverse dialysis in ratmPFC at 3, 10, and
30M (100min each) on the local extracellular DA concentration (F;n5). The application of
aCSF did not alter DA concentration (E; n 5). B, The perfusion of 3 and 30M BAY for the
entire experimental period also increased and decreased, respectively, dialysate DA concentra-
tion in different groups of rats (n 6 and 5, respectively). C, The local application of BAY (3, 10,
and 30 M) using an aCSF containing bicuculline significantly reduced extracellular DA at all
concentrations (F; n 4). The dotted line shows the effect of BAY at the same concentrations
using standard aCSF, as shown in A. Note that the absolute values of DA in the presence of
bicuculline were higher than with a normal aCSF (see Table 2). See Results for statistical analy-
sis. Data are expressed as means SEM.
10836 • J. Neurosci., November 23, 2005 • 25(47):10831–10843 Dı´az-Mataix et al. • 5-HT1A Modulation of Dopamine Activity
trations, reaching 21  4% of baseline at 30 M ( p  0.0001;
repeated-measures ANOVA) (Fig. 4C).
The perfusion of 3, 10, and 30 M BAY in the mPFC of WT
mice affected DA release similarly to rats. At the lower concen-
tration, BAY elevated extracellular DA to 176 12% of baseline,
whereas at 30 M, it reduced DA release to a maximal effect of
46 11% of baseline ( p 0.0001; repeated-measures ANOVA;
n 4). Unlike in rats, the perfusion of 10M appeared to slightly
reduce DA release. Neither of these effects was observed when
BAY was perfused in the mPFC of 5-HT1A KO mice, indicating
that the effects of the lower and higher concentrations of BAY
were attributable to the activation of 5-HT1A receptors in the
mPFC (Fig. 5).
The local perfusion of WAY-100635 (3, 10, and 30 M; four
fractions each) produced a moderate reduction in the extracellu-
lar DA concentration at the higher dose (96  7, 100  8, and
75 8% at 3, 10, and 30M; n 8; p 0.02; repeated-measures
ANOVA). However, as observed previously (Ichikawa et al.,
2001a), the subcutaneous administration of WAY-100635 (0.3
mg/kg; a dose that fully blocks 5-HT1A receptors) (Forster et al.,
1995) did not alter extracellular DA (105 2% of baseline; n 4;
data not shown).
Effects of antipsychotics on extracellular DA in the mPFC of
WT and KO mice
The intraperitoneal administration of saline did not alter the ex-
tracellular DA concentration in the mPFC of WT and 5-HT1A KO
mice (Fig. 6). Likewise, haloperidol administration (0.1 mg/kg,
i.p.) failed to alter the extracellular DA concentration in the
mPFC of WT (n 9) and 5-HT1A KO (n 7) mice. However, the
intraperitoneal administration of clozapine (5 mg/kg; n  5 for
WT and KO mice), olanzapine (3 mg/kg; n 5 for WT; n 6 for
KO), and ziprasidone (10 mg/kg; n  6 for WT and KO mice)
increased extracellular DA significantly more in the mPFC of WT
than of 5-HT1A KO mice. Actually, these doses of clozapine and
olanzapine did not significantly elevate extracellular DA in KO
mice, whereas ziprasidone moderately increased the DA concen-
tration in KO mice, but this effect was markedly lower than that
observed in WT mice. Two-way ANOVA revealed a significant
effect of the genotype on clozapine ( p 0.00001, time effect; p
0.002, group effect; p  0.00001, time-by-group interaction),
olanzapine ( p  0.0001, time effect; p  0.00001, group effect;
p 0.00001, time-by-group interaction), and ziprasidone ( p
0.00001, time effect; p  0.03, group effect; p  0.00001, time-
by-group interaction) (Fig. 6). A lower dose of olanzapine (1
mg/kg) increased extracellular DA to 138  12% in WT mice
(n  7) but not in KO mice (maximal effect, 106  4%; n  6;
data not shown).
Likewise, the local application of clozapine (300 M) and
olanzapine (100 M) in the mPFC of WT mice steadily increased
in the local DA release (Fig. 7). Clozapine perfusion increased DA
release to 280  57% and olanzapine to 180  24% of baseline
( p  0.0001; time effect for both drugs; repeated-measures
ANOVA; n 6 and 5, respectively). The perfusion of haloperidol
(30M) elevated DA release to 129 10% in the first fraction, but
4
Figure6. Effects of the intraperitoneal administration of saline (A), clozapine (CLZ; 5mg/kg;
B), olanzapine (OLZ; 3 mg/kg; C), ziprasidone (ZPS; 10 mg/kg; D), and haloperidol (HAL; 0.1
mg/kg;E) on theextracellularDAconcentration in themPFCofWT (E) and5-HT1AKO (F)mice.
Data correspond to the following number of mice per group: saline (7 WT, 7 KO), clozapine (5
WT, 5 KO), olanzapine (5WT, 6 KO), ziprasidone (6WT, 6 KO), and haloperidol (9WT, 7 KO). See
Results for statistical analysis. Data are expressed as means SEM.
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the effect faded rapidly ( p 0.09; repeated-measures ANOVA; n
5) (Fig. 9). The elevations in prefrontal DA release produced by
clozapine or olanzapine were abolished in 5-HT1A KO mice (n 5
for each drug) (Fig. 7). Two-way ANOVA revealed a significant ef-
fect of the genotype on the effect of clozapine ( p  0.003, group
effect; p 0.0001, time effect; p 0.0001, time-by-group interac-
tion) and olanzapine ( p  0.0002, group effect; p  0.0001, time
effect;p0.0001, time-by-group interaction). In contrast, the effect
of haloperidol did not differ between WT and KO mice (Fig. 7). We
could not test the local effects of ziprasidone on extracellular DA
because the vehicle used (a cyclodextrin) resulted in the clogging of
the microdialysis membranes.
Effects of atypical antipsychotics on extracellular DA in
rat mPFC
The local application of clozapine (300 M) in rat mPFC in-
creased the local extracellular DA concentration (maximal effect,
179  29% of baseline; p  0.0001, time effect; one-way,
repeated-measures ANOVA; n 5). Likewise, the local applica-
tion of olanzapine (300 M) elevated extracellular DA to 197 
23% of baseline ( p  0.0001, time effect; one-way, repeated-
measures ANOVA; n 5). The effect of clozapine was abolished
in the presence of bicuculline (n 9; p 0.03, group effect; p
0.0001, time effect; p 0.0001, time-by-group interaction; two-
way, repeated-measures ANOVA). Likewise, the coperfusion of
bicuculline totally suppressed the elevation of extracellular DA pro-
duced by olanzapine (n 7; p 0.0002, group effect; p 0.0001,
time effect; p 0.0001, time-by-group interaction) (Fig. 8).
Effect of ziprasidone and haloperidol on VTADA cell activity
in the rat: dependence on cortical integrity
The above results suggested that the increase in the activity of
mesocortical DA neurons by atypical antipsychotics involved the
Figure 7. The local application of clozapine (300M; n 6; A) and olanzapine (100M;
n 5; B) in the mPFC of WTmice (E) increased the local DA release for the entire application
period. The application of haloperidol (30 M; n 5; C) induced a moderate and transient
increase inWTmice (E) shortly after the beginning of the application. However, none of these
effects was observed when clozapine, olanzapine, or haloperidol was applied in the mPFC of
5-HT1A KO mice (n 5 for clozapine or olanzapine; n 4 for haloperidol). See Results for
statistical analysis. Data are expressed as means SEM.
Figure 8. A, As observed inWTmice, the local application of clozapine (300M) in ratmPFC
increased the local DAextracellular concentrationwhenperfusedwith a standard aCSF (E;n
5). However, this effect was attenuatedwhen clozapinewas perfused in the presence of 30M
bicuculline (F; n 9). B, Similarly, olanzapine application (300 M) in rat mPFC increased
local DA release in rats perfused with standard dialysis fluid (E; n 5). However, this effect
completely disappeared in the presence of 30 M bicuculline (F; n  7). See Results for
statistical details. Data are expressed as means SEM.
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activation of 5-HT1A receptors in the prefrontal cortex (see below
for extended discussion). As a first test of this hypothesis, we
examined the effect of the intravenous administration of haloper-
idol and ziprasidone on the activity of VTA DA cells in control
rats and in rats subjected to cortical transection.
The effect of the administration of haloperidol (0.1– 0.2 mg/
kg, i.v.) on the firing rate and burst firing was comparable in
control rats and in rats subjected to cortical transection ( p 
0.005, effect of the treatment on firing rate, nonsignificant effects
of group, and group-by-dose interaction; p 0.005, effect of the
treatment on burst firing, nonsignificant
effects of group, and group-by-dose inter-
action) (Fig. 9, Table 3). These results in-
dicate that 1) VTA DA neurons are able to
discharge in bursts in absence of cortical
inputs and 2) the effect of haloperidol did
not depend on such cortical inputs.
Ziprasidone (0.15– 0.30 mg/kg, i.v.)
also increased the overall firing rate and
burst firing in control rats, but, unlike hal-
operidol, this ability was lost in decorti-
cated rats (Fig. 9, Table 3).Two-way
ANOVA revealed a significant difference
between controls and decorticated rats
( p 0.002, treatment effect on firing rate;
p  0.002, treatment-by-group interac-
tion; p  0.006, treatment effect on burst
firing; p 0.02, effect of group; p 0.007,
group-by-dose interaction).
Discussion
The present results suggest that the activ-
ity of DA neurons in the VTA and the me-
socortical DA release are modulated by
5-HT1A receptors in the mPFC. The in-
crease in mPFC DA release produced by
the atypical antipsychotics clozapine,
olanzapine, and ziprasidone, but not hal-
operidol, seems to involve 5-HT1A recep-
tor activation. The action of a low BAY
concentration and that of atypical antipsy-
chotics seems to involve GABAergic inter-
neurons, as judged from the bicuculline
reversal.
Modulation of DA neuron activity by
5-HT1A receptors
The mPFC projects to the VTA as assessed
by electrophysiological and tracing meth-
ods (Thierry et al., 1979; Carr and Sesack,
2000a,b), and mPFC stimulation induced
burst firing in VTA DA neurons (Gariano
and Groves, 1988; Tong et al., 1996). Like-
wise, chemical and electrical stimulation
of the mPFC enhanced DA neuron activity
and DA release in the VTA (Murase et al.,
1993; Bortolozzi et al., 2005). The reduc-
tion in spontaneous bursting activity of
DA neurons by cortical transection is con-
sistent with these findings and suggests a
direct or indirect excitatory influence of
mPFC on VTA DA neurons (Fig. 1).
Previous reports show a complex influ-
ence of 5-HT on midbrain DA pathways,
mainly involving 5-HT1A (Arborelius et al., 1993a,b; Prisco et al.,
1994; Ichikawa et al., 1995; Kuroki et al., 1996; Lejeune and Mil-
lan, 1998; Rollema et al., 2000; Sakaue et al., 2000) and 5-HT2A/2C
(Ichikawa et al., 2001b; Lucas et al., 2001; Porras et al., 2002)
receptors. Here, we show that 5-HT1A receptors in the mPFC are
deeply involved in the modulation of dopaminergic activity. An
additional role of raphe 5-HT1A autoreceptors was suggested, yet
it appears controversial (Prisco et al., 1994; Sakaue et al., 2000).
Our results clearly support the involvement of prefrontal
Figure 9. Effect of the intravenous administration of ziprasidone (ZPS;A,B) and haloperidol (HAL; C,D) in sham-operated rats
(A, C) and in rats subjected to cortical transection (B, D). Arrows show the administration of drugs. The integrated firing-rate
histograms (abcissa, spikes per 10 s; ordinate, time inminutes) are shown. The top traces in each panel show representative burst
trains corresponding to 1 min recordings obtained in baseline conditions and after drug administration, as in Figure 2. The
percentage of spikes fired in bursts is also shown. Note the increase in VTA DA neuron activity in control rats and the lack of effect
of ziprasidone (but not haloperidol) in cortically transected rats. See Table 3 for statistical analysis. ZPS, Ziprasidone; HAL, halo-
peridol; WAY, WAY-100635; APO, apomorphine.
Table 3. Differential effect of the intravenous administration of ziprasidone (ZPS) and haloperidol (HAL) in
control rats and in rats subjected to cortical transection
Drug
Controls Lesioned
Basal Postdrug Basal Postdrug
ZPS (0.15–0.30 mg/kg)
Firing rate (spikes/s) 3.4 0.5 5.1 0.6* 3.3 1.1 3.3 1.1
% of spikes fired in bursts 14.6 4.6 40.8 11.6* 2.3 1.3# 3.0 2.0
n 6 6 6 6
HAL (0.1– 0.2 mg/kg)
Firing rate (spikes/s) 3.0 0.4 4.4 0.4* 2.8 0.8 3.8 0.6*
% of spikes fired in bursts 22.4 8.0 40.9 10.1* 4.7 3.0# 17.2 8.0*
n 8 8 7 7
*p 0.05, different from basal values (paired Student’s t test); #p 0.05, different from control rats (t test).
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(postsynaptic) 5-HT1A receptors, because BAY did not alter DA
cell activity or DA release in the VTA in cortically transected rats.
Indeed, 5-HT1A receptors are densely expressed in mPFC areas
that project to the VTA (Thierry et al., 1979; Amargo´s-Bosch et
al., 2004), which provides an anatomical substrate for the present
observations. Moreover, BAY increased DA cell firing at doses
higher than those suppressing 5-HT cell firing (Casanovas et al.,
2000) in accordance with the lower sensitivity of postsynaptic
versus presynaptic 5-HT1A receptors (Sprouse and Aghajanian,
1987).
5-HT1A receptor activation in the mPFC induced by local ap-
plication of agonists or raphe stimulation results in cellular hy-
perpolarization and reduction in neuronal activity (Araneda and
Andrade, 1991; Ashby et al., 1994; Puig et al., 2005). However, the
systemic administration of 5-HT1A agonists, such as 8-OH-
DPAT (Borsini et al., 1995) or BAY (Dı´az-Mataix et al., 2005),
increased the activity of prefrontal neurons. The latter study was
conducted in pyramidal neurons activated antidromically from
the VTA, which supports the notion that BAY enhances cortical
excitatory inputs into DA neurons (Fig. 10). The reasons for such
an increase in pyramidal cell activity after the systemic (but not
local) administration of 5-HT1A agonists are unclear and may
involve the activation of 5-HT1A receptors in local inhibitory
neurons (Santana et al., 2004) or in areas (e.g., hippocampus)
projecting to mPFC GABAergic neurons (Tierney et al., 2004).
Irrespectively of the mechanism(s) involved, BAY increased
the activity of pyramidal neurons in mPFC and DA neurons in
the VTA alike. This parallelism, together with the dramatic effect
of cortical transection on the effects of BAY, supports the involve-
ment of mPFC 5-HT1A receptors. It is yet unknown whether the
increase in DA cell activity is mediated by direct mPFC3VTA
afferents (Thierry et al., 1979; Carr and Sesack, 2000a) or whether
a more complex circuitry is involved (Fig. 1). In particular, the
inputs from the PPTg/LDT and VP have been shown to modu-
late, respectively, phasic and tonic inputs onto VTA DA neurons
(Floresco et al., 2003). The increase in burst firing produced by
BAY and the sensitivity of extracellular DA to nomifensine (see
below) are consistent with an increase in phasic inputs. The in-
ability of WAY-100635 to modulate baseline DA cell activity also
agrees with the absence of tonic inputs involving 5-HT1A
receptors.
Modulation of DA release by 5-HT1A receptors in the mPFC
BAY also increased DA release in the VTA and mPFC in the
experimental conditions used for DA cell recordings (intrave-
nous administration to anesthetized rats). The simultaneous in-
crease in burst firing and DA release is consistent with previous
reports (Chergui et al., 1994). Moreover, BAY increased extracel-
lular DA more markedly in the presence of nomifensine. In agree-
ment with a recent report (Floresco et al., 2003), this further
suggests that BAY increases phasic inputs onto DA neurons. The
effect of nomifensine seen in the mPFC was smaller than in the
nucleus accumbens (Floresco et al., 2003), perhaps because of the
lower density of DA fibers and DA transporter in the mPFC
(Sesack et al., 1998) and/or the distinct stimuli used in both stud-
ies. Moreover, the smaller effect of nomifensine in the VTA pos-
sibly reflects differences between terminal and somatodendritic
DA release.
BAY application in the mPFC affected local DA release in a
bell-shaped manner, suggesting the involvement of more than
one receptor population. 8-OH-DPAT also increased DA release
in the mPFC when perfused at 10 M, but no additional doses
were used (Sakaue et al., 2000). The use of 5-HT1A receptor KO
mice allowed us to clearly establish that both the stimulatory and
inhibitory effects of BAY were 5-HT1A receptor mediated. Pre-
frontal 5-HT1A receptors are involved in the long-loop modula-
tion of the 5-HT system via descending afferents to the raphe
nuclei (Ceci et al., 1994; Hajo´s et al., 1999; Celada et al., 2001).
The fact that the 5-HT release in the mPFC is reduced by BAY at
1–100 M (Casanovas et al.,1999; this study) suggests a differen-
tial regulation of 5-HT and DA neurons by mPFC 5-HT1A
receptors.
5-HT1A receptors are localized to cell bodies and/or axon hill-
ocks of pyramidal neurons (Azmitia et al., 1996; Kia et al., 1996;
Riad et al., 2000; De Felipe et al., 2001; Czyrak et al., 2003), ex-
cluding the possibility that changes in DA release are mediated by
terminal receptors. The presence of 5-HT1A receptors in mPFC
GABAergic interneurons (Santana et al., 2004), together with the
reversal of the stimulatory effect of BAY by bicuculline, suggests
that low BAY concentrations preferentially activate 5-HT1A re-
ceptors in GABA interneurons. This may eventually result in dis-
inhibition of pyramidal neurons projecting to the VTA. A higher
BAY concentration may overcome this effect, activating directly
pyramidal 5-HT1A receptors and reducing the prefrontal excita-
tory output to DA neurons. Although such cellular difference in
5-HT1A receptor sensitivity remains to be established, previous
reports are consistent with this possibility (Sprouse and Aghaja-
nian, 1986, 1987; Beck et al., 1992), perhaps because of a different
Figure10. Effect of the systemic administration of BAY on the firing of pyramidal neurons in
themPFCprojecting to theVTA (as assessed by antidromic stimulation) and onVTADAneurons.
A, Effect of the administrationof BAYon the firing rate of apyramidal neuron in themPFC.B, Bar
diagram showing the increase in the firing rate of pyramidal neurons (n 19) and the percent-
age of burst firing for DA neurons (n 11). Note the comparable effect of the various doses of
BAY x 3702 on the activity of both neuronal groups. Data from pyramidal neurons were taken
from the study by Dı´az-Mataix et al. (2005). *p 0.05 versus the respective baseline (t test
post-ANOVA).WAY,WAY-100635; Pyr, pyramidal neuron.Data are expressedasmeansSEM.
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expression level in different neuronal populations (Hoyer and
Boddeke, 1993).
Atypical antipsychotics and 5-HT1A receptors
Previous studies showed that the systemic administration of
atypical antipsychotics (but not haloperidol) increased extracel-
lular DA in the mPFC by a 5-HT1A-dependent mechanism (Rol-
lema et al., 1997, 2000; Kuroki et al., 1999; Ichikawa et al., 2001a).
Here, we show that this effect depends on the activation of
5-HT1A receptors in the mPFC. Interestingly, drugs displaying
high (ziprasidone), very low (clozapine), or negligible (olanzap-
ine) in vitro affinity for 5-HT1A receptors (Arnt and Skarsfeldt,
1998) share a common pattern of in vivo action to modulate
prefrontal DA release. Although the effect of ziprasidone is likely
attributable to the direct activation of 5-HT1A receptors, this is
not the case for clozapine or olanzapine, although clozapine (6
mg/kg) displaced 40% of the [ 11C]-WAY-100635 labeling in
monkey brain (positron emission tomography scan) despite its
700 nM in vitro affinity (Chou et al., 2003). In addition to a
partial occupancy in the case of olanzapine, other mechanisms
must be involved. Given the high coexpression of 5-HT1A and
5-HT2A receptors in the mPFC (80%) (Amargo´s-Bosch et al.,
2004), it might be thought that the concurrent blockade of
5-HT2A receptors could shift the physiological balance of 5-HT
activation toward 5-HT1A receptors. However, this possibility
seems unlikely because the selective 5-HT2A receptor antagonist
M100907 did not increase DA release (Bortolozzi et al., 2005).
Thus, the exact way in which clozapine and olanzapine interact
with 5-HT1A-mediated neurotransmission remains to be deter-
mined. However, the effect of these drugs (and that of 3M BAY)
was cancelled by bicuculline, which points toward 5-HT1A recep-
tors in GABA interneurons. This action might eventually result in
an increased excitatory cortical output to the VTA to enhance DA
neuron activity, as observed previously with atypical antipsychot-
ics (Gessa et al., 2000). The fact that the increase in DA neuron
activity produced by ziprasidone (but not by haloperidol) was
cancelled by cortical transection is consistent with this view.
Hence, haloperidol (but not ziprasidone) can increase DA neu-
ron activity in the absence of cortical inputs.
In summary, the present results show that 5-HT1A receptors in
the mPFC are deeply involved in the modulation of DA neuron
activity and of DA release in the PFC and VTA, an effect mediated
via direct mPFC3VTA inputs or long loops. This adds to previ-
ously reported targets for antipsychotic drugs such as catechol-
amine autoreceptor blockade, which also modulate DA cell activ-
ity and DA release (Gessa et al., 2000). Altogether, these results
may help to elucidate the mechanisms involved in the elevation of
mesocortical DA release produced by atypical antipsychotics.
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